Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes after single-level posterior lumbar interbody fusion in osteoporotic patients with or without paraspinal muscle atrophy: a retrospective study.

Frontiers in surgery·2026
Same author

The role of microglial Tim-3 in neuroinflammation and functional recovery after spinal cord injury.

Frontiers in neurology·2026
Same author

Quorum Sensing Regulator CinR Directly Activates the Catalase-Peroxidase Gene <i>katG</i> to Alleviate Oxidative Stress and Promote Symbiotic Nitrogen Fixation in <i>Rhizobium etli</i> CFN42.

Antioxidants (Basel, Switzerland)·2026
Same author

Study on a novel vacuum sublimation-rehydration thawing method for large yellow croaker (Larimichthys crocea) and effect of sublimation time on thawing performance.

Cryobiology·2026
Same author

Lactate-driven H3K18 lactylation promotes cisplatin resistance in bladder cancer via HNRNPF-Parkin mediated mitophagy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

Correlation analysis between CT values of cochlear bone labyrinth and auditory function and disease progression in patients with chronic suppurative otitis media.

Frontiers in medicine·2026

Related Experiment Video

Updated: Jan 16, 2026

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

1.0K

MEIS2 Modulates Oxidative Phosphorylation and ROS Generation to Affect CD8+ T Cell Antitumor Immunity in Prostate

Dengjun Han1, Changyi Jiang2, Hongjian Liu3

  • 1Urology Department, Zigong Fourth People's Hospital, Zigong, China.

The Prostate
|October 1, 2025
PubMed
Summary

Targeting MEIS2, a downregulated gene in prostate cancer (PCa), can enhance CD8+ T cell antitumor immunity. Restoring MEIS2 levels boosts T cell effectiveness against PCa by modulating oxidative phosphorylation and ROS pathways.

Keywords:
CD8+ T cellsMEIS2PCaROSoxidative phosphorylation

More Related Videos

Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Related Experiment Videos

Last Updated: Jan 16, 2026

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

1.0K
Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Prostate cancer (PCa) immunotherapy response is suboptimal.
  • MEIS homeobox 2 (MEIS2) inhibits PCa progression and affects CD8+ T cell surveillance.
  • The precise role of MEIS2 in immune regulation is unclear.

Purpose of the Study:

  • Investigate MEIS2 expression in PCa.
  • Determine MEIS2's impact on CD8+ T cell antitumor immunity.
  • Elucidate the mechanisms underlying MEIS2's regulation of T cell cytotoxicity.

Main Methods:

  • Bioinformatics and cell experiments to assess MEIS2 expression and CD8+ T cell correlation.
  • qPCR, flow cytometry, and ELISA to evaluate MEIS2's effect on T cell immunity.
  • OCR, ATP, and ROS measurements to study MEIS2's role in oxidative phosphorylation and ROS generation; rescue experiments with MCH32.

Main Results:

  • MEIS2 is downregulated in PCa and positively correlates with CD8+ T cell infiltration.
  • MEIS2 overexpression enhances CD8+ T cell cytotoxicity.
  • MEIS2 enrichment in oxidative phosphorylation and ROS pathways; MEIS2 knockdown impairs T cell immunity via increased oxidative phosphorylation and ROS.

Conclusions:

  • MEIS2 downregulation impairs CD8+ T cell antitumor immunity in PCa.
  • Targeting MEIS2 can enhance CD8+ T cell efficacy in PCa.
  • MEIS2 modulation of oxidative phosphorylation and ROS is key to its immune regulatory function.